Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | d480688d8k.htm |
| EX-99.2 - EX-99.2 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | d480688dex992.htm |
| EX-99.1 - EX-99.1 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | d480688dex991.htm |
Exhibit 99.3
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Consolidated Statements of Cash Flows
(Unaudited)
| (in thousands) |
Years Ended December 31, | |||||||||||
| 2012 | 2011 | 2010 | ||||||||||
| Cash flows from operating activities |
||||||||||||
| Net loss |
$ | (94,465 | ) | $ | (109,388 | ) | $ | (140,166 | ) | |||
| Adjustments to reconcile net loss to net cash used in operating activities |
||||||||||||
| Depreciation and amortization |
6,649 | 5,803 | 5,160 | |||||||||
| Stock-based compensation |
9,705 | 12,384 | 9,690 | |||||||||
| Other items |
287 | 226 | 459 | |||||||||
| Changes in assets and liabilities |
||||||||||||
| Accounts receivable |
1,735 | (4,216 | ) | (341 | ) | |||||||
| Inventory |
4,761 | (11,409 | ) | (6,864 | ) | |||||||
| Prepaid expenses and other assets |
1,058 | 1,874 | (1,336 | ) | ||||||||
| Accounts payable |
(1,754 | ) | (4,773 | ) | 3,637 | |||||||
| Accrued expenses and other current liabilities |
(2,054 | ) | 3,044 | 4,245 | ||||||||
| Deferred revenue |
(1,674 | ) | 2,631 | 3,221 | ||||||||
| Lease incentives and other long-term liabilities |
(1,070 | ) | 850 | 299 | ||||||||
|
|
|
|
|
|
|
|||||||
| Net cash used in operating activities |
(76,822 | ) | (102,974 | ) | (121,996 | ) | ||||||
|
|
|
|
|
|
|
|||||||
| Cash flows from investing activities |
||||||||||||
| Purchase of property and equipment |
(1,703 | ) | (9,284 | ) | (5,259 | ) | ||||||
| Purchase of investments |
(87,889 | ) | (264,071 | ) | (180,964 | ) | ||||||
| Sales of investments |
7,896 | 36,520 | — | |||||||||
| Maturities of investments |
143,488 | 243,281 | 47,973 | |||||||||
|
|
|
|
|
|
|
|||||||
| Net cash provided by (used in) investing activities |
61,792 | 6,446 | (138,250 | ) | ||||||||
|
|
|
|
|
|
|
|||||||
| Cash flows from financing activities |
||||||||||||
| Proceeds from issuance of Convertible Preferred Stock, net |
— | — | 106,145 | |||||||||
| Proceeds from issuance of Common Stock |
2,705 | 7,743 | 212,519 | |||||||||
|
|
|
|
|
|
|
|||||||
| Net cash provided by financing activities |
2,705 | 7,743 | 318,664 | |||||||||
|
|
|
|
|
|
|
|||||||
| Net (decrease) increase in cash and cash equivalents |
(12,325 | ) | (88,785 | ) | 58,418 | |||||||
| Cash and cash equivalents at beginning of period |
58,865 | 147,650 | 89,232 | |||||||||
|
|
|
|
|
|
|
|||||||
| Cash and cash equivalents at end of period |
$ | 46,540 | $ | 58,865 | $ | 147,650 | ||||||
|
|
|
|
|
|
|
|||||||
| Supplemental disclosure of non-cash investing and financing activities |
||||||||||||
| Assets acquired under facility lease |
$ | — | $ | — | $ | 2,971 | ||||||
| Additions to property and equipment under tenant improvement allowances |
— | — | 1,910 | |||||||||
| Inventory transferred to property and equipment for internal use |
1,164 | 2,756 | — | |||||||||
| Conversion of convertible preferred stock to common stock upon IPO |
— | — | 374,965 | |||||||||
| Reclassification of preferred warrants to common stock warrants |
— | — | 326 | |||||||||
| Issuance of common stock related to convertible preferred stock offering |
— | — | 281 | |||||||||
| Vesting of stock options related to early exercises |
— | 780 | 428 | |||||||||